# ClinicalTrials.gov record NCT03936049

> PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct03936049-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-07-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03936049-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03936049-liraglutide-v1.json
- Content SHA-256: `7c40bc25be426dcafc97dcabdd9a70f5f30a0a90fad2521325cfa08b46916803`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03936049 ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03936049 at 2026-07-30T19:10:42.712Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`](#source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d))

## Sources

<a id="source-ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d"></a>
- **ClinicalTrials.gov record NCT03936049 · retained source version 2023-07-27:70e1dcd6b30df121b0c5e008c061993fb8eb3775c1a42ef9e8586166ef23d17b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03936049) (`ctg-observation-nct03936049-2023-07-27-70e1dcd6b30d`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03936049." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03936049-liraglutide-v1.json SHA-256: 7c40bc25be426dcafc97dcabdd9a70f5f30a0a90fad2521325cfa08b46916803.